Priority review voucher updates: Who's won PRVs, who's bought them, and how much they're selling for
Article updated 11/30/22 to note bluebird sold a PRV to argenx for $102 million after winning two PRVs for the approvals of Skysona and Zynteglo.
The system by which the FDA awards biopharma companies with priority review vouchers for new approvals of treatments for neglected tropical diseases, rare pediatric diseases and medical countermeasures continues to thrive, more than a decade after it began.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.